Pharma BD Deal Intelligence

Endo International plc / Par Pharmaceutical Holdings, Inc.

2015 · Acquisition/Merger · $8.1B · Complete

Announcement Sentiment

Skeptical

Endo agreed to acquire Par Pharmaceutical from TPG-led investors for approximately $8.05B ($1.6B stock + $4.1B cash + $2.4B assumed debt), positioning Endo's Qualitest unit as a top-five US generics player. Closed September 28, 2015.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Impaired/Written Down

Pipeline outcome

Mixed

Assessment window: 5yr post-close.

Key facts

Announced May 18, 2015
Closed Sep 28, 2015
Deal value $8.1B
Deal type Acquisition/Merger
Therapeutic area Multiple (generics)
Indications Multiple (generics)
Key assets Par generics portfolio (high-barrier generics, sterile injectables, niche brands)
Mechanism Generic small molecules and sterile injectables

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals